Vonoprazan‐amoxicillin dual therapy versus bismuth‐containing quadruple therapy for Helicobacter pylori eradication: A systematic review and meta‐analysis
Helicobacter · 2024
DOI: 10.1111/hel.13040 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Helicobacter, 2024. Verfasst von Ben-Gang Zhou und 4 weiteren Autor:innen. Beteiligte Einrichtung: Dalian Medical University, Dalian, China. Hauptthemen laut MEDLINE: Amoxicillin, Anti-Bacterial Agents, Bismuth, Helicobacter Infections. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: National Natural Science Foundation of China, the Major Public Health Projects in Yangzhou: Screening projects of early gastrointestinal diseases (2018), the Strengthening Health Care via Science and Education Project and Clinical Medical Innovation Platform Foundation of Yangzhou.
Abstract (Originalsprache)
Background and Objective Recently, vonoprazan‐amoxicillin (VA) dual therapy has been reported as a promising approach for Helicobacter pylori ( H. pylori ) eradication. However, the effects of VA therapy versus bismuth‐containing quadruple therapy (BQT) on H. pylori eradication remains unclear. The objective of this meta‐analysis was to compare the effects of VA dual therapy with BQT for H. pylori eradication.
Methods
A comprehensive search of the literature was conducted from the beginning to September 2023, utilizing PubMed, Embase, the Cochrane Library and Web of Science database. A random‐effects model was used to perform a meta‐analysis to determine the pooled relative risk (RR) with 95% confidence intervals (CIs). Moreover, trial sequential analysis (TSA) was conducted to evaluate the conclusiveness of the H. pylori eradication rate.
Results
Six randomized controlled trials (RCTs) with 1233 patients were included. The VA therapy has similar eradication rate (ITT analysis: 87% vs. 85.7%, RR = 1.01, 95% CI: 0.93–1.09, p = 0.84; PP analysis: 92.5% vs. 93.2%, RR = 1.00, 95% CI: 0.94–1.06, p = 0.97) and compliance (RR = 1.01, 95% CI: 0.99–1.03, p = 0.32) compared to BQT. The VA therapy group had a significantly lower incidence of total adverse events than the BQT group (16.3% vs. 40.0%, RR = 0.45, 95% CI: 0.37–0.55, p < 0.00001). The TSA result showed that the effect was conclusive.
Conclusions
Current evidence indicated that VA therapy is just as successful as BQT in eliminating H. pylori , yet it has fewer adverse events and similar compliance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dalian Medical University, Dalian, China.
- Department of Gastroenterology, Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, China.
ORCID-Profile: Ben-Gang Zhou
Förderung
- National Natural Science Foundation of China
- the Major Public Health Projects in Yangzhou: Screening projects of early gastrointestinal diseases (2018)
- the Strengthening Health Care via Science and Education Project and Clinical Medical Innovation Platform Foundation of Yangzhou
Zitieren
APA
Zhou, B. G., Jiang, X., Ding, Y. B., She, Q., & Li, Y. Y. (2024). Vonoprazan‐amoxicillin dual therapy versus bismuth‐containing quadruple therapy for Helicobacter pylori eradication: A systematic review and meta‐analysis. Helicobacter. https://doi.org/10.1111/hel.13040
Vancouver
Zhou BG, Jiang X, Ding YB, She Q, Li YY. Vonoprazan‐amoxicillin dual therapy versus bismuth‐containing quadruple therapy for Helicobacter pylori eradication: A systematic review and meta‐analysis. Helicobacter. 2024. doi:10.1111/hel.13040
BibTeX
@article{Zhou2024,
author = {Zhou, Ben-Gang and Jiang, Xin and Ding, Yan-Bing and She, Qiang and Li, Yao-Yao},
title = {Vonoprazan‐amoxicillin dual therapy versus bismuth‐containing quadruple therapy for Helicobacter pylori eradication: A systematic review and meta‐analysis},
journal = {Helicobacter},
year = {2024},
doi = {10.1111/hel.13040}
}
EUVIMED